Brainsway (NASDAQ:BWAY) Stock Price Up 13% on Analyst Upgrade

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY)’s share price traded up 13% during mid-day trading on Wednesday after BTIG Research raised their price target on the stock from $18.00 to $20.00. BTIG Research currently has a buy rating on the stock. Brainsway traded as high as $16.95 and last traded at $16.93. 425,392 shares traded hands during mid-day trading, an increase of 159% from the average session volume of 164,121 shares. The stock had previously closed at $14.98.

Several other research firms also recently issued reports on BWAY. Zacks Research upgraded shares of Brainsway from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Brainsway in a research report on Friday, July 17th. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. Weiss Ratings restated a “buy (b-)” rating on shares of Brainsway in a research note on Tuesday, July 21st. Finally, New Street Research reiterated a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $16.33.

Key Brainsway News

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: BrainsWay reported record second-quarter 2026 revenue of $17.1 million, up 35% year over year and above analysts’ $16.54 million consensus. The results and operational highlights point to continued demand for the company’s Deep TMS platform. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: The company raised or reaffirmed a favorable outlook for fiscal 2026 revenue at $68 million to $70 million, modestly above the $67.8 million analyst consensus. This guidance suggests management expects growth to continue through the year. BrainsWay Q2 2026 Earnings Call Transcript
• Positive Sentiment: BTIG Research raised its price target for BWAY from $18 to $20 and assigned a “Buy” rating. The new target implies meaningful upside from the stock’s recent trading level and may reinforce investor confidence in the company’s growth prospects. BTIG Research price target update
• Neutral Sentiment: The earnings call and recent results provide additional details on BrainsWay’s commercial execution, profitability and 2026 outlook. Investors will likely focus on whether the company can convert strong revenue growth into consistent earnings expansion. BrainsWay Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter EPS was $0.07, below the $0.10 consensus estimate. While net margin was 15.68% and return on equity was 12.28%, the earnings shortfall could limit enthusiasm, particularly with the stock trading at a relatively elevated forward valuation. BrainsWay second-quarter 2026 earnings release

Institutional Investors Weigh In On Brainsway

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Brainsway in the 1st quarter valued at about $40,000. Ballast Advisors LLC acquired a new position in Brainsway during the first quarter worth about $55,000. Raymond James Financial Inc. purchased a new stake in shares of Brainsway in the second quarter valued at about $85,000. Bank of America Corp DE purchased a new position in shares of Brainsway during the 3rd quarter worth approximately $107,000. Finally, Royal Bank of Canada raised its position in shares of Brainsway by 1,145.9% during the 4th quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after purchasing an additional 7,735 shares during the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

Brainsway Stock Performance

The company has a 50-day moving average of $15.03 and a 200-day moving average of $14.30. The stock has a market capitalization of $688.25 million, a price-to-earnings ratio of 49.00 and a beta of 1.24.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The firm had revenue of $17.11 million for the quarter, compared to analysts’ expectations of $16.54 million. As a group, analysts expect that Brainsway Ltd. Sponsored ADR will post 0.33 earnings per share for the current year.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.